BC
VTGN icon

Bartlett & Co’s VistaGen Therapeutics VTGN Stock Holding History

Bartlett & Co’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-500
Closed -$14K – 766
2018
Q1 		$14K Hold
500
– – ﹤0.01% 576
2017
Q4 		$17K Buy
500
+167
+50% +$5.51K ﹤0.01% 540
2017
Q3 		$16K Buy
+333
New +$17.5K ﹤0.01% 546

Other funds holding VTGN

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
CA
Corrado Advisors Ramsey, New Jersey $192M AUM 20.53% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bartlett & Co's VTGN Position: Q2 2018 in Review

Bartlett & Co sold out of VistaGen Therapeutics (VTGN) in Q2 2018, closing a stake of 500 shares — an estimated $14K sold.

Bartlett & Co first reported a position in VTGN in Q3 2017 and held it in 3 quarters. The position peaked at $17K in Q4 2017. 22 funds tracked by Wall St. Rank hold VTGN as of Q2 2018.

  • Bartlett & Co reported no remaining VistaGen Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Bartlett & Co sold 500 VistaGen Therapeutics shares in Q2 2018, an estimated $14K.
  • Bartlett & Co first reported a position in VistaGen Therapeutics in Q3 2017 and held it in 3 quarters.
  • Bartlett & Co's VistaGen Therapeutics position peaked at $17K in Q4 2017.
  • 22 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2018.

Based on Bartlett & Co's 13F filing for Q2 2018, filed 31 Jul 2018.